Drug Discovery World

MAY 25, 2023

DNA Script: SYNTAX DNA printing platform Using the company’s EDS technology, the SYNTAX platform can synthesise up to 96 highly accurate, ready-to-use DNA oligos with maximum lengths of up to 120nt in less than 24 hours in the laboratory. The platform works with the SYNTAX Hi-Fidelity reagent kits for synthesising longer oligos.

Production 52

Production Reagent DNA Drugs 52

Pharmaceutical Technology

FEBRUARY 14, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Key innovation: Leading companies in nanoparticles for drug delivery. Bristol-Myers Squibb is the leading patent filer in nanoparticles for drug delivery.

Drug Delivery 147

Drug Delivery Drugs Drug Delivery Systems FDA Approval 147

Drug Discovery World

AUGUST 14, 2023

While CGT is still an emerging market, its growth has accelerated over the last five years, resulting in a wave of products approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Driven by the rapid pace of innovation, the market for CGTs is expected to grow from $4.4

Gene Therapy 52

Gene Therapy Marketing Gene DNA 52

Pharmaceutical Technology

JUNE 23, 2022

Researchers at the University of New Hampshire (UNH) have found that a repurposed drug, CCG-50014, could hinder the activity of a key enzyme of the SARS-CoV-2 virus, which causes Covid-19. Utilising a currently available drug compound in a new way is called drug repurposing.

Drugs 130

Drugs Protein Genome Genomics 130

pharmaphorum

AUGUST 10, 2021

Europe market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according to Andrew Obenshain, president of its severe genetic diseases unit. market and will wind down in Europe. market and will wind down in Europe.

Gene Therapy 135

Gene Therapy Gene Marketing Genetic Disease 135

Drug Discovery World

JUNE 8, 2023

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ Join this free roundtable to learn about the biggest opportunities for the future of drug discovery and development. What can we expect from the cell & gene therapy market?

Development 52

Development Drugs Gene Therapy DNA 52

Drug Discovery World

JUNE 27, 2023

Hosted by DDW and supported by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ Join this free roundtable to learn about the biggest opportunities for the future of drug discovery and development. What can we expect from the cell & gene therapy market?

Drugs 52

Drugs Gene Therapy DNA Antibody 52

Outsourcing Pharma

FEBRUARY 1, 2024

A company building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (pathway) has announced a further extension to its series B financing round.

DNA 90

DNA Protein Drugs Regulation 90

BioPharma Reporter

DECEMBER 16, 2020

Thermo Fisher Scientific today announced the construction of a new cGMP plasmid DNA manufacturing facility at its site in Carlsbad, California.

DNA 69

DNA Manufacturing Production Drugs 69

Drug Discovery World

JUNE 7, 2023

Hosted by DDW and sponsored by DNA Script, join us for this free-to-attend roundtable to learn about the biggest opportunities for the future of drug discovery and development. What can we expect from the cell & gene therapy market? Is it true that the next era will belong to antibody drug conjugates?

Development 52

Development Gene Therapy Drugs DNA 52

Drug Discovery World

JUNE 15, 2023

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ Join this free roundtable to learn about the biggest opportunities for the future of drug discovery and development. What can we expect from the cell & gene therapy market?

Development 52

Development Drugs Gene Therapy DNA 52

Drug Discovery World

JUNE 22, 2023

Hosted by DDW and supported by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ Join this free roundtable to learn about the biggest opportunities for the future of drug discovery and development. What can we expect from the cell & gene therapy market?

Drugs 52

Drugs Gene Therapy DNA Antibody 52

Roots Analysis

JANUARY 21, 2024

With fourteen approved drugs and several drug candidates being evaluated under different stages of development, antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. In this context, the role of the linker molecule and the conjugation technology used is pivotal.

Antibody 40

Antibody Recombinant DNA Technology Drugs Marketing 40

pharmaphorum

OCTOBER 31, 2022

Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing. Alice Zhang.

Genome 136

Genome Genomics Drugs RNA 136

Delveinsight

JULY 26, 2021

However, antibiotics are the only available treatment options in the Uncomplicated Urinary Tract Infections market to cater to such a large patient pool. Some of the most commonly prescribed antibiotics in the Uncomplicated Urinary Tract Infection therapy market include the combination drug trimethoprim and sulfamethoxazole, trimethoprim, ?-lactams,

Marketing 93

Marketing Bacteria Vaccination Vaccine 93

XTalks

NOVEMBER 28, 2023

Kesin Pharma has obtained approval from the US Food and Drug Administration (FDA) for its oral suspension antibiotic drug Likmez (metronidazole), designed for patients with dysphagia and difficulty swallowing. Likmez offers a safer alternative by mitigating the associated risks linked to off-label drug compounding.

FDA Approval 103

FDA Approval Bacteria DNA Drugs 103

Pharmaceutical Technology

MAY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Periodontitis drugs. However, not all innovations are equal and nor do they follow a constant upward trend.

Drugs 130

Drugs Vaccination Vaccine Antibody 130

Roots Analysis

FEBRUARY 21, 2022

Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine. The various advantages of NGS are briefly described below: Next Generation Sequencing (NGS) Library Preparation Kits Market – Roots Analysis.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

The Pharma Data

NOVEMBER 26, 2020

26, 2020 /PRNewswire/ — BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link ‘ s AccuFind COVID-19 IgG antibody test in a healthcare setting. At present, most antibody tests on the market require samples to be sent to a lab for analysis.

DNA 52

DNA Antibody Research Genome 52

Drug Discovery World

FEBRUARY 6, 2024

As AI-designed drugs start to enter large-scale clinical trials, DDW’s Diana Spencer investigates how new digital tools are reinventing and reshaping drug discovery for the future. Quris-AI, which combines patient-on-a-chip, AI and real-time nano-sensing technologies to predict the safety and efficacy of drug candidates.

Marketing 69

Marketing Medicine Genome Genomics 69

Medical Xpress

MAY 1, 2023

A decade after scientists developed the ability to edit DNA using the CRISPR sequence, the first drugs using the technique are approaching the market, with the potential to transform the lives of people with certain genetic illnesses. But questions of ethics, access, and pricing remain.

DNA 75

DNA Genetics Scientist Marketing 75

Pharmaceutical Technology

JUNE 15, 2023

The US Food and Drug Administration (FDA) has accepted Ipsen’s supplemental new drug application (sNDA) for the Onivyde regimen as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC) patients. The regulator has set 13 February 2024 as a Prescription Drug User Fee Act goal date for the review of Ipsen’s sNDA.

DNA 130

DNA Regulation Trials Drugs 130

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nedisertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nedisertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

FEBRUARY 23, 2023

GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. The company provides end-to-end contract development and manufacturing organisation (CDMO) services from the discovery to the commercialisation of drugs.

Vaccination 289

Vaccination Vaccine Gene Therapy Manufacturing 289

pharmaphorum

NOVEMBER 9, 2022

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable levels of the virus compared to an earlier readout.

Drugs 98

Drugs Sales Trials DNA 98

pharmaphorum

JANUARY 21, 2022

The US regulator has granted biliary tract cancer therapy Silmitasertib orphan drug designation. There are currently no treatments for this rare cancer, and the US food and Drug Administration (FDA) hopes that pharmaceutical firm Senhwa’s drug will meet the significant need for new biliary tract cancer options.

Drugs 64

Drugs Clinical Development DNA Regulation 64

Pharmaceutical Technology

MARCH 2, 2023

According to GlobalData, Phase III drugs for Rheumatoid Arthritis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Rituximab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Production 100

Production DNA Clinical Trials Clinical Trials 100

Pfizer

JANUARY 27, 2023

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner. AUTHORIZED USE The U.S.

Marketing 75

Marketing Production Drugs Licensing 75

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.

Drugs 76

Drugs Life Science Gene Therapy Genome 76

World of DTC Marketing

FEBRUARY 7, 2021

DTC marketers can tap into AI to help deliver relevant messages to certain audiences, but they shouldn’t let AI do all their thinking. Drug Discovery and Manufacturing: It helps in the initial screening of drug compounds to the predicted success rate based on biological factors. Measuring RNA, DNA quickly.

Doctors 164

Doctors Doctor Drugs Marketing 164

Drug Discovery World

JUNE 16, 2023

LP-184 is the first of Lantern’s drug candidates to be developed entirely internally, with the assistance of Lantern’s AI and ML platform RADR, to advance to a first-in-human Phase Ia trial. The post FDA clearance of IND application for solid tumour drug appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs Clinical Trials Clinical Trials Trials 52

BioPharma Reporter

JANUARY 17, 2022

Andelyn Biosciences says the FDA's acceptance of its GMP plasmid DNA drug master file (DMF) enables the CDMO to vertically integrate its clientsâ manufacturing process, condensing timelines for developers to begin manufacturing to just three months.

Gene Therapy 105

Gene Therapy Development DNA Gene 105

pharmaphorum

OCTOBER 2, 2020

Vaccibody, which is also entitled to tiered royalties on sales of any marketed products, will develop the DNA-based individualised neoantigen vaccines until the end of phase 1b. The Roche unit will also bear all costs for trials, filings, manufacturing and marketing after the completion of the phase 1b study.

Vaccination 59

Vaccination Vaccine Immune Response Drugs 59

pharmaphorum

OCTOBER 26, 2021

Molnupiravir is already filed for approval in the US and Canada – where Merck is known as MSD – amid hopes that the drug could be used to protect vulnerable people with mild or moderate COVID-19 from developing severe disease with a drug that can be delivered outside the hospital. The drugmaker has already sold 1.7

Drugs 105

Drugs DNA Trials Medicine 105

pharmaphorum

JUNE 27, 2022

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a “functional cure” for the widespread disease.

DNA 124

DNA Drugs Sales Licensing 124

pharmaphorum

AUGUST 28, 2020

An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widespread disease. Meanwhile, five of 12 previously-untreated patients had 2-log (90%) or a greater reduction in HBV DNA. billion in potential milestones.

Drugs 52

Drugs DNA Licensing Licensing 52